Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial
在脓毒性休克患者中应用非中和性肾上腺髓质素抗体adrecizumab (HAM8101)的安全性和耐受性:AdrenOSS-2 2a期生物标志物指导试验
期刊:Intensive Care Medicine
影响因子:21.2
doi:10.1007/s00134-021-06537-5
Laterre, Pierre-François; Pickkers, Peter; Marx, Gernot; Wittebole, Xavier; Meziani, Ferhat; Dugernier, Thierry; Huberlant, Vincent; Schuerholz, Tobias; François, Bruno; Lascarrou, Jean-Baptiste; Beishuizen, Albertus; Oueslati, Haikel; Contou, Damien; Hoiting, Oscar; Lacherade, Jean-Claude; Chousterman, Benjamin; Pottecher, Julien; Bauer, Michael; Godet, Thomas; Karakas, Mahir; Helms, Julie; Bergmann, Andreas; Zimmermann, Jens; Richter, Kathleen; Hartmann, Oliver; Pars, Melanie; Mebazaa, Alexandre